Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated ...
Jun 4, 2021
0
1